News filtered by category

Scaling Pharma 4.0 digital manufacturing cannot be treated as a matter of extending a successful pilot across the plant. For pharmaceutical manufacturers, moving digital initiatives from proof of concept to production requires designing for validation, data governance, integration, and adoption from the outset, and governing the portfolio with the discipline to stop weak pilots early and advance strong ones quickly.

Cybersecurity has become an essential component of regulatory compliance for pharmaceutical and medical device manufacturers. This white paper examines the growing connection between GxP cybersecurity, data integrity, and quality assurance, including FDA Section 524B requirements, EU GMP Annex 11, and Computer Software Assurance (CSA) guidance. It explores the risks created when cybersecurity responsibilities fall between IT and quality teams, leaving critical systems vulnerable to security incidents and regulatory findings. It also outlines practical strategies for strengthening cybersecurity controls, establishing clear accountability, and integrating security risk management into existing quality systems. Learn how organizations can address compliance gaps, protect regulated data, and improve cybersecurity readiness across GxP environments.

Transitioning from clinical development to commercial manufacturing presents significant challenges for pharmaceutical, biologics, and cell and gene therapy manufacturers. This white paper examines the quality system gaps that can emerge as products advance toward commercialization, including process validation, change control, data integrity, and continued process verification. It also outlines a phase-based approach to assessing quality system maturity, aligning quality improvements with clinical milestones, and strengthening FDA pre-approval inspection readiness. Learn how organizations can address compliance gaps early, reduce the risk of approval delays, and build quality systems capable of supporting commercial manufacturing.

FDA Computer Software Assurance (CSA) and EU GMP Annex 11 are reshaping expectations for computerized systems in regulated life sciences. This white paper examines where the two frameworks align and diverge, including requirements for audit trails, cybersecurity, access management, and supplier oversight. It also outlines how organizations can build a harmonized, risk-based control strategy that supports both FDA and European compliance while reducing duplicated remediation and unnecessary rework.

The FDA’s Quality Management System Regulation (QMSR) changes more than terminology. This white paper breaks down the changes that go beyond a simple clause-mapping exercise, including retained FDA provisions and expanded access to internal quality records. It also outlines practical steps organizations can take to assess gaps, strengthen compliance, and prepare for FDA inspections under the new framework.

AI is becoming part of manufacturing and quality workflows, but its use needs clear controls. This white paper explains how life sciences organizations can define intended use, assess model credibility, maintain human oversight, and manage AI systems throughout their lifecycle.

FDA Computer Software Assurance gives life sciences organizations a risk-based approach to software validation that focuses resources on the systems and functions that matter most. This white paper examines the FDA’s CSA guidance, its relationship to traditional Computer System Validation, and practical steps for putting risk-based software assurance into practice.

Data integrity failures can create consequences far beyond the quality department. This white paper examines FDA enforcement trends, common data integrity gaps, audit trail review, computerized system controls, and practical steps pharmaceutical and biologics manufacturers can take to strengthen data governance and reduce compliance risk.

Supplier oversight is becoming increasingly complex for pharmaceutical, biotechnology, and other FDA-regulated organizations that rely on contract manufacturers, laboratories, and critical suppliers. Traditional supplier quality management practices, including periodic audits and questionnaires, may leave significant gaps between formal reviews as regulatory status, performance, and data integrity risks change.

FDA inspection readiness cannot be treated as a short-term preparation exercise before an expected inspection. For pharmaceutical, biotechnology, and medical device organizations, maintaining continuous inspection readiness means building a quality system that produces evidence of compliance during everyday operations, not just when an inspection is approaching.

An effective corrective and preventive action (CAPA) program should do more than document that an issue was addressed. It should demonstrate that the root cause was identified, the appropriate corrective action was implemented, and the fix actually worked. As regulatory scrutiny increases, organizations need CAPA processes built around evidence, meaningful effectiveness checks, and investigations that can withstand inspection.